Melanoma Pipeline Expands as 150+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight's "Melanoma Pipeline Insights 2026" report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in the Melanoma Pipeline landscape. It covers the Melanoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Melanoma research. Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Melanoma Pipeline Report
• On July 29, 2026- Innovent Biologics (Suzhou) Co. Ltd. conducted a phase II Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients.
• On July 27, 2026- Jennarex Biotherapeutics initiated a phase I/II study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
• On July 23, 2026- Regeneron Pharmaceuticals highlighted a phase 3 study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name OpdualagTM and approved for the treatment of melanoma in adults and children.
• DelveInsight's Melanoma pipeline report depicts a robust space with 150+ active players working to develop 180+ pipeline therapies for Melanoma treatment.
• The leading Melanoma Companies such as Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier and IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US Inc. and others.
• Promising Melanoma Therapies such as Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.

Download for updates and be a part of the revolution in cancer care @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Melanoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Melanoma Pipeline Report also highlights the unmet needs with respect to the Melanoma.

Melanoma Overview
Melanoma is a malignant tumour arising from melanocytes. It is among the most common forms of cancer in young adults and typically presents as a new or changing pigmented (brown or black) skin lesion, but there are other presentations (amelanotic or desmoplastic) with a different clinical picture. When melanoma starts in the skin, the disease is called cutaneous melanoma. Melanoma is more aggressive than basal cell skin cancer or squamous cell skin cancer. Melanoma of the skin can occur anywhere on the body. Unusual moles, exposure to natural sunlight or artificial sunlight (such as from tanning beds) over long periods of time, and family history can affect the risk of melanoma. Melanoma may also occur in mucous membranes thin, moist layers of tissue that cover surfaces such as the lips.

Melanoma Emerging Drugs Profile
• ABP-206: Amgen
ABP-206 is an investigational biologic being developed by Amgen for the treatment of melanoma. It is designed as a biosimilar candidate to target immune checkpoint pathways involved in tumor growth. By modulating the immune system, ABP-206 aims to enhance anti-tumor responses in patients with advanced or metastatic melanoma. The drug is currently in clinical development, with ongoing studies evaluating its safety, efficacy, and comparability to the reference therapy. The drug is currently is in Phase III for the treatment of Melanoma.

• IBI363: Innovent Biologics
IBI363 is the world's first PD-1/IL-2α-bias bispecific fusion protein independently developed by Innovent Biologics. It integrates two key functions: blockade of the PD-1/PD-L1 pathway and activation of the IL-2 signaling pathway. The IL-2 arm of IBI363 has been engineered to retain affinity for IL-2 Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm enables simultaneous PD-1 blockage and selective delivery of IL-2. This differential targeting strategy exploits the fact that newly activated tumor-specific T cells co-express PD-1 and IL-2α, which allows for more precise and efficient targeting and activation of this T cell subset. Currently, the drug is in Phase II stage of its development for the treatment of Melanoma.

• EVX-01: Evaxion Biotech A/S
EVX-01 is an investigational cancer immunotherapy developed by Evaxion Biotech A/S for the treatment of melanoma. It is a personalized peptide-based vaccine designed using AI to identify tumor-specific neoantigens unique to each patient. By stimulating a targeted T-cell immune response, EVX-01 aims to improve tumor recognition and destruction. The therapy is currently in clinical development, with studies assessing its safety, immunogenicity, and efficacy in melanoma patients. Currently, the drug is in Phase III for the treatment of Melanoma.

• PF-08046031: Pfizer
PF-08046031 is an investigational antibody-drug conjugate (ADC) developed by Pfizer for the treatment of advanced melanoma and other solid tumors. It targets the CD228 antigen, enabling selective delivery of a cytotoxic agent to tumor cells. This mechanism is designed to enhance tumor cell killing while minimizing systemic exposure. The drug is currently in early-phase clinical development, with studies evaluating its safety, tolerability, and preliminary efficacy in melanoma patients.

• BT02: Biotroy Therapeutics
BT02 is an investigational oncology therapy being developed by Biotroy Therapeutics for the treatment of melanoma. It is designed to target tumor-specific pathways involved in cancer cell growth and survival, aiming to inhibit disease progression. The therapy is being explored for its potential to enhance anti-tumor immune responses or directly suppress tumor activity. BT02 is currently in early-stage development, with ongoing research focused on evaluating its safety and therapeutic potential in melanoma.

• ADP-600: Adaptimmune
ADP-600 is an investigational engineered T-cell receptor (TCR) therapy developed by Adaptimmune for the treatment of melanoma and other solid tumors. It targets the PRAME antigen, which is commonly expressed in melanoma cells, enabling precise recognition and killing of cancer cells by engineered T-cells. The therapy is designed to enhance T-cell potency and persistence to improve anti-tumor responses. ADP-600 is currently in preclinical development, with plans to advance into early-phase clinical trials evaluating its safety and efficacy.

Learn more about Melanoma Drugs opportunities in our groundbreaking Melanoma research and development projects @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Melanoma Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma Treatment.
• Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Melanoma Drugs under development are based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Melanoma market.

Melanoma Companies
Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier and IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US Inc. and others.

The Melanoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Melanoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we're transforming the future of oncology @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Melanoma Pipeline Report
• Coverage- Global
• Melanoma Companies- Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier and IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US Inc. and others.
• Melanoma Therapies- Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
• Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of the Melanoma Pipeline on our website, @ https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. ABP-206: Amgen
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. IBI363: Innovent Biologics
12. Early Stage Products (Phase I)
13. Comparative Analysis
14. PF-08046031: Pfizer
15. Inactive Products
16. Melanoma Key Companies
17. Melanoma Key Products
18. Melanoma- Unmet Needs
19. Melanoma- Market Drivers and Barriers
20. Melanoma- Future Perspectives and Conclusion
21. Melanoma Analyst Views
22. Melanoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.